|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INSERM U800, Villeneuve d’Ascq, France; Université Lille I, Villeneuve d’Ascq, France; and Equipe Labellisee Ligue Nationale Contre le Cancer, Villeneuve d’Ascq, France
1Correspondence: Laboratoire de Physiologie Cellulaire, INSERM U800, Bâtiment SN3, Université des Sciences et Technologies de Lille, 59655 Villeneuve d’Ascq Cedex, France. E-mail: flourakismatt@yahoo.fr; fabien.vancoppenolle@univ-lille1.fr; natacha.prevarskaya{at}univ-lille1.fr
SPECIFIC AIM
The aim of this study was to explore the role of the translocon complex [present on the endoplasmic reticulum (ER) membrane and involved in protein translocation during translation] in the activation of SOCE (store operated calcium entry). We addressed the hypothesis about a possible functional link between the passive leakage via the translocon and SOCE stimulation.
PRINCIPAL FINDINGS
1. Thapsigargin and EGTA deplete ER calcium stores via translocon
Thapsigargin and EGTA are the commonly used drugs that induce calcium release from the ER. Nevertheless, the mechanism and the molecular counterpart of this calcium leak are still ill-defined.
Using confocal calcium imaging, we have demonstrated that by lowering the number of opened translocons by anisomycin (an inhibitor of peptidyl-transferase, leaving the translocon closed) neither thapsigargin nor calcium chelator EGTA could induce calcium release from the ER. However, the inhibition of the calcium leak via the translocon by anisomycin did not reduce the IP3-evoked ER store depletion.
These results suggest that the translocon is the main ER channel, which mediates passive Ca2+ leak induced by thapsigargin and calcium chelators.
2. Ca2+ leakage through translocon activates SOCE
To further explore the putative role of translocon in Ca2+ homeostasis, it was also potentially rewarding to examine whether passive store depletion via the translocon could activate SOCE through SOC (store operated channels).
Previous studies undertaken by our laboratory have put forward the hypothesis of the coexistence of two functionally distinct types of SOC, depending on the mode of store depletion: (i) SOCCC (conformational coupling), involving "active" dynamic protein–protein interaction between IP3 receptors and SOC, and (ii) SOCCIF (calcium influx factor) activated by iPLA2-regulated signaling stimulated following passive leakage from intracellular stores.
In this study, we tried to determine whether ER store depletion via translocon could activate SOCE and what would be the mechanism of "translocon-to-SOC" coupling.
In our experiments, lowering the number of opened translocon by anisomycin resulted in a decrease of the SOC current density evaluated during whole-cell recording. Anisomycin pretreatment reduced both EGTA-evoked ISOC (1.05±0.18 pA/pF under control condition (n=13) and 0.36±0.2 pA/pF after anisomycin pretreatment (n=11)) and thapsigargin-evoked ISOC [0.73±0.08 pA/pF (n=4) under control conditions and 0.22±0.182 pA/pF after anisomycin pretreatment (n=6)] (Fig. 1
A, B, and D). The same pretreatment was unable to reduce the IP3-evoked ISOC (0.93±0.178 pA/pF under control conditions (n=14) and 0.8±0.27 pA/pF after anisomycin pretreatment (n=15), (Fig. 1C and D
).
|
3. iPLA2 activity is required for SOCE stimulation by passive Ca2+ leakage via the translocon
We also investigated whether Ca2+ passive leakage occurring specifically through the translocon could activate the SOC current via iPLA2 activation. We measured the SOCE using barium imaging with Fluo 4 (5 µM) as a Ca2+ cytoplasmic dye. As shown in Fig. 2
, puromycin induced a rise of [Ba2+]in, which was absent in a barium-free solution (Fig. 2A
). In anisomycin-pretreated cells, this increase was inhibited by 76.7 ± 5.3% (n=43), however, in BEL-pretreated cells (a specific iPLA2 inhibitor) the same increase was reduced by 90.3±1.4% (n=47) (Fig. 2B
). Thapsigargin induced an increase similar to that evoked from puromycin in [Ba2+]in (Fig. 2C
). This thapsigargin-evoked SOCE was also reduced in anisomycin-pretreated and BEL-pretreated cells (respectively, 45.1 ± 5.3% (n=74) and 88.3 ± 1.4% (n=49), Fig. 2D
). A summary of this data is presented in Fig. 2E
. The same pretreatment could not reduce the IP3(100 µM)-evoked SOCE. These results were confirmed by patch-clamp experiments (data not shown).
|
The results of this study show that calcium leakage occurring via the translocon could activate SOCCIF current (but not SOCcc current), thus highlighting our hypothesis that calcium leakage occurring via the translocon is a first step for SOCCIF activation.
CONCLUSION AND SIGNIFICANCE
In summary, for the first time, we have demonstrated that the passive calcium leak translocon-channel mediates the thapsigargin- and EGTA-induced calcium release. We have also shown that calcium release that occurs via the translocon activates store-operated calcium current. This is the first characterization of SOCE triggered by a passive calcium leak channel with identified molecular structure in the ER. Figure 3
demonstrates a "translocon–SOC activation" hypothesis consistent with our data. Our results also hint to a new Ca2+ pathway with a crucial role in Ca2+ homeostasis: Ca2+ leakage occurring through the translocon may induce CIF formation and/or CIF release from the ER, which dissociates calmodulin from iPLA2ßbeta; and so leads to the production of lysophospholipids and to SOCCIF activation.
|
As the translocon complex is present in yeast and mammalian cells, our findings suggest that Ca2+ homeostasis using translocon pathways is a common phenomenon.
FOOTNOTES
2 These authors equally contributed to this work. ![]()
To read the full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.05-5254fje
This article has been cited by other articles:
![]() |
K. Singaravelu, C. Lohr, and J. W. Deitmer Regulation of store-operated calcium entry by calcium-independent phospholipase A2 in rat cerebellar astrocytes. J. Neurosci., September 13, 2006; 26(37): 9579 - 9592. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |